SAN DIEGO, Nov. 24 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. is scheduled to present at the 21st Annual Piper Jaffray Health Care Conference at The New York Palace in New York City on December 1, 2009 at 1:00 p.m. Eastern Time.
A live audio webcast of this presentation will be accessible on the Investors page of the Company’s website at www.optimerpharma.com. Replays of this presentation will be available at the same location for 30 days following the meeting.
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Pruvel(TM) (prulifloxacin) is an antibiotic which has completed two Phase 3 clinical trials for the treatment of infectious diarrhea in travelers. Additional information can be found at http://www.optimerpharma.com.
CONTACT: Christina Donaghy, Corporate Communications Manager, or John D.
Prunty, Chief Financial Officer & VP Finance, both of Optimer
Pharmaceuticals, Inc., +1-858-909-0736; or Jason I. Spark, Vice President,
Porter Novelli Life Sciences, +1-619-849-6005
Web site: http://www.optimerpharma.com/
